GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (XCNQ:RVV) » Definitions » EV-to-EBITDA

Revive Therapeutics (XCNQ:RVV) EV-to-EBITDA : -7.32 (As of May. 27, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Revive Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Revive Therapeutics's enterprise value is C$8.41 Mil. Revive Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.15 Mil. Therefore, Revive Therapeutics's EV-to-EBITDA for today is -7.32.

The historical rank and industry rank for Revive Therapeutics's EV-to-EBITDA or its related term are showing as below:

XCNQ:RVV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.94   Med: 0   Max: 0
Current: -7.32

XCNQ:RVV's EV-to-EBITDA is ranked worse than
100% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.57 vs XCNQ:RVV: -7.32

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Revive Therapeutics's stock price is C$0.025. Revive Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.003. Therefore, Revive Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Revive Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Revive Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics EV-to-EBITDA Chart

Revive Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.05 -10.82 -8.55 -8.13 -2.27

Revive Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.16 -3.09 -2.27 -6.81 -8.89

Competitive Comparison of Revive Therapeutics's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revive Therapeutics's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's EV-to-EBITDA falls into.



Revive Therapeutics EV-to-EBITDA Calculation

Revive Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.409/-1.148
=-7.32

Revive Therapeutics's current Enterprise Value is C$8.41 Mil.
Revive Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revive Therapeutics  (XCNQ:RVV) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Revive Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.025/-0.003
=At Loss

Revive Therapeutics's share price for today is C$0.025.
Revive Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.003.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Revive Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Revive Therapeutics (XCNQ:RVV) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
Executives
Michael Frank Director, Senior Officer

Revive Therapeutics (XCNQ:RVV) Headlines

No Headlines